AUNA's YTD Rally Highlights Optimism, But DeepValue Report Urges Caution Amid Mexico Struggles

What happened

AUNA's stock has rallied 21.5% year-to-date, outperforming the industry, as a recent article cites steady growth in Peru, early turnaround signs in Mexico, and improved liquidity boosting confidence. However, the DeepValue master report reveals that Mexico operations remain under pressure, with third-quarter 2025 revenue down 12% year-over-year and adjusted EBITDA falling 29%, driven by operational disruptions at Doctors Hospital from HIS/ERP migration issues. Management has noted sequential improvements in surgeries and oncology services, but utilization continues to decline, and the financial conversion to profitability is unproven. While a $765 million debt refinancing has enhanced liquidity, leverage stays high at approximately 3.6x net debt to EBITDA, with a $500 million Mexico investment plan raising risks of equity dilution. The article's upbeat narrative contrasts with the report's data, underscoring that investors must look beyond short-term sentiment to assess the sustainability of Mexico's recovery and capital structure discipline.

Implication

The YTD surge in AUNA's stock price is not yet backed by improved Mexico profitability, which remains critical for the investment thesis. High leverage and the looming need for funding a $500 million expansion could lead to equity dilution, eroding per-share value. Key catalysts include resolving operational issues and achieving year-over-year revenue growth in Mexico by the second quarter of 2026, as outlined in the DeepValue report. Without these milestones, the stock faces downside risk, with a bear case value of $3.50 versus a base case of $6.50, highlighting the importance of patience. Therefore, maintaining a 'WAIT' stance is advisable, with an attractive entry only below $4.60 to account for execution and dilution risks.

Thesis delta

The DeepValue report's 'WAIT' rating remains unchanged, as the new article offers no substantive data to alter the core thesis that Mexico must demonstrate financial recovery and leverage improvement. While the rally reflects market optimism, it does not address the persistent operational challenges or funding overhangs detailed in the filings. Investors should view this as noise until upcoming financials provide verifiable proof of turnaround, keeping the thesis focused on execution risks and capital structure concerns.